Marion Subklewe, MD, Ludwig Maximilian University Hospital Munich, Munich, Germany, discusses her work investigating targeting Wilms' tumor 1 (WT1) with a T-cell bispecific antibody (WT1-TCB): ex vivo and in vivo potency by bivalent recognition of peptide-MHC complexes from an intracellular tumor antigen at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.
